Logo

AstraZeneca Reports the First Patients Dosing of Saphnelo (anifrolumab) in the P-III (IRIS) Trial for the Treatment of Lupus Nephritis

Share this

AstraZeneca Reports the First Patients Dosing of Saphnelo (anifrolumab) in the P-III (IRIS) Trial for the Treatment of Lupus Nephritis

Shots:

  • The 1st patient has been dosed in the P-III (IRIS) trial to evaluate anifrolumab vs PBO in 360 patients aged 18 to 70yrs. with LN. The objective of the study is to evaluate the efficacy & safety of anifrolumab when added to standard therapy in adults with active Class III or IV LN
  • The results from the P-II (TULIP-LN1) trial evaluate anifrolumab which failed to meet its 1EPs (69% vs 70%) & the higher dose showed clinically numeric improvements across multiple 2EPs & exploratory EPs
  • Saphnelo is a fully human mAb that binds to subunit 1 of the type I IFN receptor & inhibits its function. The therapy has been approved in the US, Japan, EU & Canada for SLE while regulatory reviews are underway in other countries globally

Ref: AstraZeneca | Image: AstraZeneca

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions